2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist 2023, 29: e507-e513. PMID: 37971411, PMCID: PMC10994263, DOI: 10.1093/oncolo/oyad300.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsBRAF/MEK inhibitionImmune checkpoint inhibitorsBRAFV600E/K mutationsMEK inhibitorsCheckpoint inhibitorsClinical variablesMEK inhibitionRetrospective single-institution analysisIpilimumab/nivolumabFirst-line settingFirst-line therapyFirst-line treatmentMetastatic melanoma patientsLong-term outcomesPretreatment clinical variablesSingle-institution analysisStratification of patientsK mutationCombined BRAFECOG PSMedian OSRECIST 1.1Immunotherapy regimenClinical characteristics
2014
Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008
Lott JP, Wititsuwannakul J, Lee JJ, Ariyan S, Narayan D, Kluger HH, Lazova R. Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008. Journal Of The American Academy Of Dermatology 2014, 71: 1077-1082. PMID: 25308882, PMCID: PMC6133655, DOI: 10.1016/j.jaad.2014.08.026.Peer-Reviewed Original ResearchConceptsMalignant melanomaSpitzoid malignant melanomasSpitz neviClinical characteristicsRetrospective cohort studyMultivariate logistic regressionMalignant melanoma diagnosisSelect patientsCohort studyYounger patientsClinical featuresSingle institutionMale genderMelanomaSmall lesionsLogistic regressionNeviSmall sample sizeLesionsMelanoma diagnosisDiagnosisUnmeasured confoundingPatientsDescriptive statisticsAgeMEK targeting in N-RAS mutated metastatic melanoma
Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Molecular Cancer 2014, 13: 45. PMID: 24588908, PMCID: PMC3945937, DOI: 10.1186/1476-4598-13-45.Peer-Reviewed Original ResearchConceptsN-RASShort-term cultureMelanoma patientsMelanoma culturesYale Cancer CenterMetastatic melanoma patientsTime of presentationOngoing clinical trialsProtein kinase pathway activationN-RAS mutationsB-RafPan-RAF inhibitorTerm cultureKinase pathway activationConclusionsThe prognosisBrain metastasesClinical characteristicsMetastatic diseasePathologic dataWorse prognosisCancer CenterMetastatic melanomaClinical trialsMutant melanomaMelanoma cell cultures